Tag: Drug Discovery And Development

Alzheimer’s Drug Discovery Foundation and Harrington Discovery Institute Invite Proposals for 2022 ADDF-Harrington Scholar Award

sarah JonasAnnouncement

Harrington Discovery Institute at University Hospitals and the Alzheimer’s Drug Discovery Foundation (ADDF) announce a joint request for proposals for the 2022 ADDF-Harrington Scholar Award. The ADDF-Harrington Scholar Award is designed to accelerate the translation of innovative research that could treat, prevent, or slow Alzheimer’s disease or related dementias.

The Request for Proposal (RFP) is open to academic investigators at accredited medical centers, research institutions, and universities in the United States, Canada, and the United Kingdom. Researchers working on drug development programs that are relevant to, but not presently focused on, the Alzheimer’s field are also encouraged to apply. This award provides a combination of financial support and expert drug development guidance to provide the best chance to move research beyond the bench to the bedside.

This class of microbes is an underexploited source of new bioactive compounds

sarah JonasExpert Pitch

Demand for new kinds of antibiotics is surging, as drug-resistant and emerging infections are becoming an increasingly serious global health threat. Researchers are racing to reexamine certain microbes that serve as one of our most successful sources of therapeutics: the…

SLAS Discovery’s September Special Collection “Applications of Biophysics in Early Drug Discovery” Now Available

sarah JonasResearch Tip Sheet

The September edition of SLAS Discovery is a Special Collection featuring the cover article, “Applications of Biophysics in Early Drug Discovery” by Geoffrey A. Holdgate (AstraZeneca, Macclesfield, UK) and Christian Bergsdorf, Ph.D. (Novartis Institutes for Biomedical Research, Basel, Switzerland).

Harnessing the Power of Proteins in our Cells to Combat Disease

sarah JonasResearch Results

A lab on UNLV’s campus has been a hub of activity in recent years, playing a significant role in a new realm of drug discovery — one that could potentially provide a solution for patients who have run out of options.

National Virtual Biotechnology Laboratory Symposium, October 28

sarah JonasAnnouncement

A virtual symposium to highlight the impact the U.S. Department of Energy’s (DOE) National Virtual Biotechnology Laboratory (NVBL) has had utilizing the unique capabilities of the DOE to tackle the science and technology challenges associated with COVID-19, and to discuss areas in which the NVBL can have impact in the future. The event is aimed at the S&T community, media, and the general public.

September Edition of SLAS Discovery Highlights “Applications of Functional Genomics for Drug Discovery”

sarah JonasResearch Results

September’s edition of SLAS Discovery features the cover article, “Applications of Functional Genomics for Drug Discovery” by Ami M. Kabadi, Ph.D., (Element Genomics), Eoin McDonnell, Ph.D. (Element Genomics), Christopher L. Frank, Ph.D., (Element Genomics), and Lauren Drowley, Ph.D., (UCB Biosciences). The article reviews how functional genomic tools are better able to understand the biological interplay between genes, improving disease modeling and identifying novel drug targets.

The Tri-Institutional Therapeutics Discovery Institute, Inc. Renews Partnerships with Takeda and Bridge Medicines, LLC

sarah JonasAnnouncement

To date, work done within the Tri-I TDI has resulted in the launch of two New York City–based companies and the licensing of six therapeutic discovery programs.